top of page

Social Responsibility

PSTx was chartered for social benefit by its founders. 

Paradigm Shift Therapeutics is chartered with a commitment to social benefit, which will be achieved by sharing the value of our discoveries more equitably among all the stakeholders in the drug development process, especially patients. 

Our scientific goal is to develop a transformational therapy for cancer through our award-winning science and our novel approach to a promising cancer target.  Our strategy leverages existing networks of translational and clinical development resources at government and academic institutions through public-private partnerships to advance candidates from discovery to the clinic. Our business model promises a better return on taxpayer investment in publicly-funded research by developing therapies in an innovative, capital efficient, and cost controlled manner followed by fair and transparent pricing. This kind of social benefit commercialization strategy is successful in many other industries, and we strive to be among the first to pioneer it in biopharma. 

Our success will demonstrate that social benefit can sustainably guide product development and commercialization in the drug industry and that there is room for both profits and patients. The PSTx founder’s vision is that a CD47 therapeutic will be the first in a portfolio of a sustainable business committed to socially responsible drug development.


Paradigm Shift Therapeutics (PSTx) has been awarded a federal grant which requires that we
make the following information available on this website:

Grant Number: 1U01CA218259-01A1
Principal Investigator: Thomas W Miller, PHD and Principal Scientist at PSTx
Key Personnel: Teresa L Burgess, PHD and CSO at PSTx; Catherine L Farrell PHD and CEO at PSTx
Entity: Paradigm Shift Therapeutics, LLC

Drs. Miller, Burgess and Farrell are all equal co—owners of PSTx. PSTx is not a publicly-traded company and the value of that interest is one whose value cannot be readily determined through references to public prices or other reasonable measures of fair market value. The PI and Key Personnel commit to objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from their FCOI in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F.

bottom of page